Dermatology

NEJM Journal Club

Questions discussed in this category

How do you counsel patients regarding the cardiovascular and cancer risks associated with tofacitinib?

Should the use of avacopan be limited to those patients at increased risk of steroid toxicity given the anticipated high cost of this medication?

ADVOCATE trial

1 Answer available

How should the results of the ADVOCATE trial be applied in AAV patients who receive rituximab induction and maintenance therapy?

In the ADVOCATE trial, patients were not re-dosed with rituximab.

1 Answer available

Are there particular subsets of AAV patients in which avacopan is more effective?

E.g., MPO vs PR3, newly diagnosed vs relapsed, renal involvement. Acknowledge that the ADVOCATE study was not powered to detect these differences, but...

1 Answer available

Papers discussed in this category

N Engl J Med, 2021 Feb 18

Avacopan for the Treatment of ANCA-Associated Vasculitis.

N Engl J Med,

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.

Dermatology

NEJM Journal Club

Questions discussed in this category

Papers discussed in this category

Related Topics in Dermatology